Form 4: TOI Chief Medical Officer Executes Stock Sale
Insider Transaction Report
Yale Podnos, Chief Medical Officer of The Oncology Institute, Inc., sold 23,451 shares of common stock via a 10b5-1 plan.
Summary
- Yale Podnos, Chief Medical Officer of The Oncology Institute, Inc. (TOI), sold 23,451 shares of common stock.
- The shares were sold at a volume-weighted average price of $5.3769 per share.
- The transaction occurred on June 8, 2026.
- Following the sale, the reporting person retains beneficial ownership of 259,527 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned 10b5-1 program, which is a standard practice for executive financial planning.
Positives
- The sale was conducted pursuant to a pre-arranged Rule 10b5-1(c) trading plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.
Negatives
- The sale represents a reduction in the equity stake held by a key member of the executive leadership team.
Risks
- Executive stock sales can sometimes be perceived negatively by the market as a signal of management's view on the company's future valuation.
Future Outlook
No forward-looking guidance or operational outlook was provided in this filing.
Industry Context
StockSavvy.ai notes that executive stock sales under 10b5-1 plans are routine corporate governance events and generally do not reflect a change in company strategy or operational performance.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for executives at publicly traded healthcare companies to manage personal liquidity while maintaining compliance with SEC regulations.
Stakeholder Impact
- Minimal impact on shareholders as the sale was pre-planned and represents a small portion of the executive's total holdings.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 08/26/2025 | Date the Rule 10b5-1(c) trading plan was adopted. |
| 06/08/2026 | Date of the stock sale transaction. |
| 06/09/2026 | Date the Form 4 was signed and filed. |
Keywords
TOI, The Oncology Institute, Insider Trading, Form 4, Yale Podnos, Chief Medical Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.